Blog
RSS FeedPosted by Michael Wonder on 27 Feb 2024
Voxelotor for the treatment of patients with sickle cell disease (draft guidance)
27 February 2024 - NICE has issued further draft guidance on the use of voxelotor following an appeal hearing in ...
Posted by Michael Wonder on 27 Feb 2024
Tafamidis for the treatment of patients with transthyretin amyloidosis with cardiomyopathy
27 February 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 26 Feb 2024
Setmelanotide acetate for the treatment of people with obesity and hyperphagia associated with Bardet-Biedl syndrome (draft guidance)
22 February 2024 - NICE has published further draft guidance on the use of setmelanotide acetate. ...
Posted by Michael Wonder on 22 Feb 2024
A cancer doctor’s view of why reform of PHARMAC is vital
23 February 2024 - Late last year, many of my colleagues returned from the largest international gathering of doctors who ...
Posted by Michael Wonder on 22 Feb 2024
Up to 14,000 people could benefit from the first treatment for severe alopecia recommended by NICE
22 February 2024 - Thousands of people with severe hair loss due to alopecia areata are set to benefit from a ...
Posted by Michael Wonder on 21 Feb 2024
Talazoparib tosylate for the treatment of patients with advanced BRCA mutation positive HER2 negative breast cancer (final guidance)
21 February 2024 - NICE has published final evidence-based recommendations on the use of talazoparib tosylate (Talzenna) for the treatment ...
Posted by Michael Wonder on 15 Feb 2024
Updates to the HTA review research and analysis papers collection: emerging health technologies
15 February 2024 - The draft paper 'Emerging Health Technologies' developed to support the deliberations of the HTA Review Reference ...
Posted by Michael Wonder on 13 Feb 2024
SMC - February 2024 decisions
12 February 2024 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...
Posted by Michael Wonder on 10 Feb 2024
Isatuximab in combination with pomalidomide and dexamethasone for the treatment of patients with relapsed and refractory multiple myeloma
9 February 2024 - NICE is reviewing its guidance on the use of isatuximab for the treatment of patients with ...
Posted by Michael Wonder on 07 Feb 2024
Olaparib in combination with abiraterone acetate for the treatment of patients with hormone relapsed metastatic prostate cancer
7 February 2024 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) in combination with abiraterone ...
Posted by Michael Wonder on 07 Feb 2024
Nivolumab with relatlimab for the treatment of patients with unresectable or metastatic melanoma
7 February 2024 - NICE has published final evidence-based recommendations on the use of nivolumab with relatlimab (Opdualag) for the ...
Posted by Michael Wonder on 07 Feb 2024
Belumosudil mesylate for the treatment of patients with chronic graft versus host disease
7 February 2024 - NICE has published final evidence-based recommendations on the use of belumosudil mesylate (Rezurock) for the treatment ...
Posted by Michael Wonder on 06 Feb 2024
Updates to the HTA Review: consultation 2 survey
6 February 2024 - Access to the HTA Review Consultation 2 online survey is now available on the Office of ...
Posted by Michael Wonder on 06 Feb 2024
Updates on NICE and SMC collaboration on MTA for cystic fibrosis
1 February 2024 - On 19 December 2023, we advised that NICE would be liaising with key stakeholders to determine ...
Posted by Michael Wonder on 05 Feb 2024
Linzagolix choline for the treatment of patients with moderate to severe symptoms of uterine fibroids
5 February 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...